key: cord-0795289-it88xq9t
authors: Wang, Zhe; Chen, Yuqing; Yang, Jing; Han, Yanxi; Shi, Jiping; Zhan, Shaohua; Peng, Rongxue; Li, Rui; Zhang, Runling; Li, Jinming; Zhang, Rui
title: External Quality Assessment for Molecular Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Clinical laboratories
date: 2020-10-26
journal: J Mol Diagn
DOI: 10.1016/j.jmoldx.2020.10.008
sha: b1edce3fec25891607b7127d272d0d0bab353717
doc_id: 795289
cord_uid: it88xq9t

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a huge threat to public health. Viral nucleic acid testing is the diagnostic gold standard and can play an important role in the prevention and control of this infection. In this study, bacteriophage MS2 virus-like particles encapsulating specific RNA sequences of SARS-CoV-2 and other coronaviruses were prepared by genetic engineering. The assessment panel, consisting of four positive samples with concentrations of 2.8, 3.5, 4.2 and 4.9 log(10) copies/mL and five negative samples with other human coronaviruses, was prepared and distributed to evaluate the accuracy of routine viral RNA detection. Results of 931 panels from 844 laboratories were collected. The overall percent agreement (OPA), positive percent agreement (PPA) and negative percent agreement (NPA), defined as the percentage of agreement between the correct results and total results submitted for all, positive and negative samples were 96.8% (8109/8379), 93.9% (3497/3724), and 99.1% (4612/4655), respectively. For samples with concentrations of 4.9 and 4.2 log(10) copies/mL, the PPAs were > 95%. However, for 3.5 and 2.8 log(10) copies/mL, the PPAs were 94.6% (881/931) and 84.9% (790/931), respectively. For all negative samples, the NPAs were > 95%. Thus, the majority of laboratories can reliably detect SARS-CoV-2. However, further improvement and optimization is required to ensure the accuracy of detection in panel members with lower concentrations of viral RNA.

In December 2019, patients exhibited unexplained pneumonia in Wuhan, Hubei Province, China. 1 After virus isolation and genome sequencing were performed, a new coronavirus was discovered and named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 2 4 Epidemiological studies have shown that SARS-CoV-2 has strong human-to-human transmission capability, 5 and common symptoms of COVID-19 include fever, dry cough, fatigue, and dyspnea, while severe infection leads to respiratory failure and even death. 2 To date, SARS-CoV-2 has resulted in more than 14,300,000 confirmed cases and has caused 600,000 deaths throughout the world (World Health Organization, (as of March 26, 2020 ) and laboratory-developed tests (LDTs) was conducted when clinical laboratories were enrolled in EQA to ensure that the virus-like particles (VLPs) were suitable for all the assays used in participating laboratories. ORF1ab, N and E genes were selected based on the assays used by participants, including the sequences recommended by the WHO 

The armored RNA digested by DNase I and RNase A was subjected to 1% agarose gel electrophoresis, and the single band that was observed indicated the construction of stable simulated samples (Supplemental Figure S1 ). RT-PCR was performed on nucleic acids extracted from VLPs, and the sequencing results of amplified products provided further evidence of the successful packaging of target segments (data not shown instructions for use (IFU), while other laboratories used "modified" extraction reagents, which were different from those in the manufacturer's IFU.

Of the 931 completed data sets, the performances were found to be competent in 748 

The laboratories participating in this EQA used a total of five detection methods, and the PPAs of each method are shown in Table 3 . RT-PCR showed PPAs higher than 95% for samples with 4.9, 4.2 and 3.5 log 10 copies/mL and 85.1% (773/908) for 2.8 log 10 copies/mL.

RT-LAMP, high-throughput sequencing, time-of-flight mass spectrometry, and microarray techniques all demonstrated high PPAs for samples with 4.9 and 4.2 log 10 copies/mL, J o u r n a l P r e -p r o o f respectively. However, for 3.5 and 2.8 log 10 copies/mL, the PPAs varied considerably.

For samples with 4.9 and 4.2 log 10 copies/mL, the PPAs of magnetic bead-based and column-based nucleic acid extraction methods were higher than 95%; however, for 3.5 and 2.8 log 10 copies/mL, the rates of both decreased (Figure 1) . For each positive sample, the percent agreement of the laboratories using magnetic bead-based extraction method was higher than that of the laboratories using column-based extraction method (Figure 1) . The overall PPA of the laboratories using "unmodified" extraction reagents in the manufacturer's IFU (94.1%, 1284/1364) was higher than that of the laboratories using "modified" extraction reagents (91.7%, 2163/2360), and the situation was similar for positive samples at each concentration (Figure 1 ).

Among the 931 received data sets, 823 employed 9 assays approved by the NMPA and the others applied laboratory developed test (LDT) assays (Supplemental Table 1 and 2).

The PPA of NMPA-approved assays (94.3%, 3106/3292) was higher than that of LDTs (90.5%, 391/432), which revealed a statistical difference in performance between them (P=0.002). We analyzed the NMPA-approved assays employed by more than 20 laboratories.

For samples with 4.9 and 4.2 log 10 copies/mL, the PPAs of the six assays were all above 95%.

However, for 3.5 and 2.8 log 10 copies/mL, the rates were variable ( copies/mL), respectively. In general, assays with LODs below or equal to 200 copies/mL performed better than those with LODs above 200 copies/mL. However, there were also a number of exceptions. For example, XABT showed a PPA of 90.0% (18/20) in detecting the sample with 3.5 log 10 copies/mL, which was lower than that of Daan (97.3%, 218/224) and

Sansure (100%, 258/258). Since the claimed LODs of these six assays are different, ranging from 2.0-3.0 log 10 copies/mL, the PPAs of the samples with the same multiples of their individual LODs were compared to evaluate the robustness of these assays, which is defined as the ability to proceed optimally despite slight variation in conditions, such as differences in extraction reagents and expertise of personnel. For samples with nucleic acid concentrations higher than or equal to 6.4× the LOD, all assays could achieve percent agreements of more than 95%, except XABT assays (Supplemental Table 3 ). However, for samples with nucleic acid concentrations equal to 3.2× the LOD, the percent agreements of the Sansure, ZJ, BioGerm and XABT assays differed greatly, ranging from 75.0% to 96.9% (Supplemental from the laboratories using ZJ assays had a single positive gene target, 41.7% (5/12) had two positive gene targets, and 50% (6/12) showed all three gene targets as positive.

Ideally, quality control materials should be obtained from clinical samples after inactivation, but this approach is not feasible because of the limited number of clinical samples and potential infection. 12 Armored RNA is similar in structure to natural viruses, resistant to RNase A, and unable to replicate by itself both in vivo and in vitro. 13 Therefore, armored RNA is stable for storage and transport, is not pathogenic and is able to participate in the whole nucleic acid extraction process. In previous studies related to external quality assessment for nucleic acid detection, VLPs have been used as a substitute for infectious pathogens. 8, 9, 14 In this study, we prepared bacteriophage VLPs as simulated samples for SARS-CoV-2 and other coronaviruses. Subsequently, an EQA on the proficiency of SARS-CoV-2 nucleic acid detection in laboratories was conducted.

In this study, the viral load of simulated positive samples ranged from 2.8-4.9 log 10 copies/mL. The SARS-CoV-2 virus replicates actively in the early stage of infection and reaches a peak concentration (approximately 4.0-7.0 log 10 copies/mL) in the respiratory tract early after the onset of symptoms. Then, the viral load gradually decreases to lower than 4.0 log 10 copies/mL in the late stage of infection. 15 The viral loads of respiratory samples ranged from 2.8 to 11.1 log 10 copies/mL, showing a median of 4.9 log 10 copies/mL in throat swabs and 5.9 log 10 copies/mL in sputum. The lowest detected viral load was 2.8 log 10 copies/mL in the late stages of infection. 10 Another study showed that the average viral load of respiratory samples was 4.6 log 10 copies/mL, and the minimum viral load in the later stage of the disease was 3.2 log 10 copies/mL. 11 A dynamic analysis of sputum samples from 44 confirmed patients showed that the viral load was 3.1-4.7 log 10 copies/mL in the early and late stages. 16 Therefore with low concentration to find the errors in the whole analytical process. In this study, the two laboratories used high-positive plasmids as quality control, which were not able to monitor nucleic acid extraction process and the detection of low positive samples. The false negative results might be due to problems in the test systems, such as extraction process, competency of staff and performance of equipment.

Nucleic acid extraction is one of the most critical steps to ensure the reliability of molecular diagnosis. 17 The percentage of the laboratories using automated assays in the magnetic bead-based extraction method was 77.2% (481/623), which was considerably higher than the percentage (6.6%, 14/212) of the laboratories using automated assays in the column-based extraction method. This might lead to a higher percent agreement of the laboratories using magnetic bead-based extraction method. Automated extraction has some advantages, such as easy operation, reduced working time, and high-throughput capability.

Most importantly, automated extraction systems are often able to recover a more consistent yield of nucleic acids, avoiding differences caused by operators. 18 A study comparing the efficiency of two automated methods and two manual methods for extracting enterovirus RNA showed that the automated extraction method has similar or better results than the manual method. 19 We also observed that 36.6% (341/931) of laboratories used "unmodified" extraction reagents in the manufacturer's IFU, which showed a higher PPA than those using "modified" extraction reagents. When extraction reagents different from those in the IFU were introduced into the testing process, the entire integrated test system was modified. The Standards Institute (CLSI), modified FDA-cleared or approved assays required full validation. 21 Therefore, we suggest that the laboratories use "unmodified" extraction reagents or validate the whole system thoroughly before the "modified" extraction reagents are applied.

Overall Table 2 ). For assays involved in this study, the overall PPA based on four positive samples of NMPA-approved assays was slightly higher than that for LDTs (94.3% vs.

90.5%); in addition, the performance of the six most frequently used NMPA-approved assays copies/mL, and the PPA was 100% when detecting samples with nucleic acid concentrations of 1-2× the LOD in clinical evaluation. 23 In this study, the majority of the assays did not achieve a 95% detection rate for samples with 3.5 and 2.8 log 10 copies/mL, except for the Sansure, BGI, and Daan assays used in clinical practice ( Table 4 ). The varying abilities of assays to detect weakly positive samples should be due to the difference in the claimed LODs of these assays. However, the assays with the same claimed LODs also performed differently (Supplemental Table 3 ). The claimed LODs of Sansure and XABT are both 2.3 log 10 copies/mL. When detecting samples with nucleic acid concentrations of 2.8 log 10 copies/mL (3.2× the LOD), the PPAs of the laboratories using Sansure assays were 96.9%, considerably higher than the percent agreements (75.0%) of the laboratories using XABT assays. The PPA of ZJ and BioGerm for the sample with a concentration of 2.8 log 10 copies/mL was only 74.1%

and 76.9%, respectively, because the claimed LODs of ZJ and BioGerm were both 3.0 log 10 copies/mL. However, for the samples with concentrations of 3.2× the LOD, the PPAs of ZJ and BioGerm assays were 92.8% and 88.5%, respectively, considerably higher than that of the XABT assay. Sansure, ZJ and BioGerm assays appeared to have better robustness than the XABT assay, which is important for the assays to be applied more consistently in different laboratories.

Currently, RT-PCR assays approved by the U.S. FDA EUA and NMPA mainly target the ORF1ab, N, E, and S genes. 15 In this study, the targets of assays involved the ORF1ab, N, and E genes. Among the six assays, BGI is the only assay with a single target, namely, ORF1ab, with a high PPA and reproducibility. In theory, assays with multiple target regions are able to detect each target of a positive sample. However, due to the primer design and the competition of primer set in the multiplex reaction, it is normal for an assay to have different amplification efficiencies for each target, which causes differences in the sensitivity for each target. 24, 25 Multiple pairs of primers in a PCR analysis will also increase the probability of mispairing and nonspecific amplification products (primer dimers). 26, 27 In addition, enzymes, primers, the optimal salt ion concentration, and cycle numbers required for primers based on different genes might be different. Thus, when targets with higher sensitivity are positive, regions with lower sensitivity might be undetected, especially in weakly positive samples. In this study, inconsistent PPAs in the ORF1ab, N and E genes occurred in all multitarget assays ( Table 4 ). For the assays that report positive results based on positive amplification of both J o u r n a l P r e -p r o o f 31 Table 3 The results of four positive samples submitted by the laboratories using different detection methods

Number of data sets Table 4 The results of four positive samples submitted by the laboratories using the six most frequently used NMPA assays Assays 2020-I (4.9 log 10 copies/mL) 2020-H (4.2 log 10 copies/mL) 2020-C (3.5 log 10 copies/mL) 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet

Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses: The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting wuhan

Transmission of 2019-nCoV infection from an asymptomatic contact in Germany

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Armored long RNA controls or standards for branched DNA assay for detection of human immunodeficiency virus type 1

External quality assessment for the molecular detection of MERS-CoV in China

External quality assessment for Avian Influenza A (H7N9) Virus detection using armored RNA

Viral load of SARS-CoV-2 in clinical samples

A novel delivery platform based on Bacteriophage MS2 virus-like particles

External Quality Assessment of Molecular Detection of Ebola Virus in China

Molecular and Serological Assays for SARS-CoV-2: Insights from Genome and Clinical Characteristics

Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients

Current Nucleic Acid Extraction Methods and Their Implications to Point-of-Care Diagnostics

Advanced Techniques in Diagnostic Microbiology

Valsamakis A: Comparison of automated and manual nucleic acid extraction methods for detection of enterovirus RNA

Comparison of Five Commercial Nucleic Acid Extraction Kits for the PCR-based Detection of Burkholderia Pseudomallei

Molecular Diagnostic Methods for Infectious Diseases

Establishment and Application of a Universal Coronavirus Screening Method Using MALDI-TOF Mass Spectrometry

Comprehensive Review on Current Interventions, Diagnostics, and Nanotechnology Perspectives against SARS-CoV-2

Multiallelic synthetic quality control material: lessons learned from the cystic fibrosis external quality assessment scheme

Challenges in designing a Taqman-based

Varicella-zoster virus

Scalable transcriptional analysis routine--multiplexed quantitative real-time polymerase chain reaction platform for gene expression analysis and molecular diagnostics

The elimination of primer-dimer accumulation in PCR

real-time reverse-transcription polymerase chain reaction; RT-LAMP, reverse transcription-loop-mediated isothermal amplification

NMPA: National Medical Products Administration; BGI: BGI Bio-tech Co